Libby Baney Discusses Future of Remote Prescription Regulation Under New Administration With Modern Healthcare

In the article, “3 Biden Healthcare Regulations Trump Will Have to Finalize,” government and regulatory partner Libby Baney discussed the potential future of remote prescription access during President-elect Donald Trump’s second term with Modern Healthcare.

The article noted that the Drug Enforcement Agency delayed final action on telehealth regulation, instead opting to grant providers limited authority to prescribe controlled substances remotely. That regulation is set to expire at the end of the year. Trump’s first administration is likely to be amenable to the industry’s request for favorable regulation, the article noted.

“It’s a huge question mark as to the philosophy of it,” Baney said. “Do you lean towards access, or do you lean towards diversion and control? I don’t think they’re inconsistent with each other. But how to talk that fine line so you don’t create another epidemic for controlled substances that are easily able to be received through telemedicine is a real question.”

The full article is available to Modern Healthcare subscribers.